Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)

Next Previous
Trial Profile

A Phase 1b/2 Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Tucatinib (Primary)
  • Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Adverse reactions
  • Acronyms DB-07; DESTINY-Breast07
  • Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

  • 14 Feb 2025 Planned End Date changed from 31 Jan 2025 to 31 Jan 2030.
  • 11 Jun 2024 Planned End Date changed from 2 Jul 2025 to 31 Jan 2025.
  • 04 Jun 2024 Results(n=125) from interim analysis of dose-expansion phase assesing T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top